5 completed, 1 recruiting, 1 terminated. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 5, Recruiting 1, Terminated 1 |
Follow iloperidone: new trials by email Literature Review of iloperidone trials Research Report on iloperidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Open-Labeled Iloperidone in Adolescents Iloperidone - Schizophrenia, Bipolar I Disorder | Phase 4 | Recruiting | Vanda Pharmaceuticals | 100 | 2023-05-24 | 2026-10-01 |
| Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo olanzapine, iloperidone, Placebo - Healthy | Phase 4 | Completed | New York State Psychiatric Institute | 31 | 2012-11-01 | 2017-03-20 |
| Iloperidone in Mixed States of Bipolar Disorder iloperidone - Bipolar Disorder | Phase 4 | Completed | The University of Texas Health Science Center at San Antonio | 41 | 2012-04-01 | 2018-02-08 |
| Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability Iloperidone, Placebo - Major Depressive Disorder | Phase 4 | Completed | Maurizio Fava, MD | 20 | 2012-04-01 | 2017-04-11 |
| Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia Iloperidone - Schizophrenia, Schizoaffective Disorder | Phase 4 | Terminated | Northwestern University | 19 | 2012-04-01 | 2015-07-10 |
| Switching to Iloperidone From Other Antipsychotics in Schizophrenia iloperidone - Schizophrenia | Phase 4 | Completed | Novartis | 501 | 2010-08-01 | 2013-03-15 |
| Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine - Psychotic Disorders | Phase 4 | Completed | Johns Hopkins University | 127 | 2009-01-01 | 2017-04-25 |
Schizophrenia (3) · Psychotic Disorders (2) · Bipolar Disorder (1) · Depressive Disorder, Major (1) · Obesity (1) · Tooth, Impacted (1) · Weight Gain (1)
Johns Hopkins University (1) · Maurizio Fava, MD (1) · New York State Psychiatric Institute (1) · Northwestern University (1) · Novartis (1) · The University of Texas Health Science Center at San Antonio (1) · Vanda Pharmaceuticals (1)
United States (7)
Charles Bowden, MD (1) · Christoph Correll, MD (1) · Gloria Reeves, MD (1) · Jeffrey Lieberman, MD (1) · John Csernansky, MD (1) · Linmarie Sikich, MD (1) · Mark A. Riddle, MD (1) · Marla Hochfeld, MD, MD (1) · Maurizio Fava, MD (1)
PMID 26913173, PMID 29444618, PMID 7726714
R01MH080270 (1)